Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hyperammonemic encephalopathy associated with valproate acid].

M T Osuna1, J Burcet, L Ramió

  • 1Sección de Neurología, Hospital Dr. Josep Trueta Girona, Palma de Mallorca, Spain. teresa_osuna_pulido@hotmail.com

Neurologia (Barcelona, Spain)
|July 3, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reperfusion therapy in acute ischaemic stroke due to cervical and cerebral artery dissection: Results from a Spanish multicentre study.

Neurologia·2022
Same author

Reperfusion treatment in acute ischaemic stroke due to cervical and cerebral artery dissection: results of a Spanish national multicentre study.

Neurologia·2020
Same author

Predicting Motor Outcome in Acute Intracerebral Hemorrhage.

AJNR. American journal of neuroradiology·2019
Same author

Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.

Acta neurologica Scandinavica·2018
Same author

Outcome of cancer-related seizures in patients treated with lacosamide.

Acta neurologica Scandinavica·2017
Same author

Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.

Seizure·2017

Valproate acid (VPA) can cause hyperammonemic encephalopathy (HE) even with normal liver function and therapeutic drug levels. Monitoring ammonium is crucial for diagnosing HE in patients on VPA.

Area of Science:

  • Neurology
  • Clinical Toxicology
  • Biochemistry

Background:

  • Valproate acid (VPA) is a widely used antiepileptic and mood-stabilizing drug.
  • Hyperammonemic encephalopathy (HE) is a serious neurological condition characterized by elevated ammonia levels in the blood.
  • VPA-induced HE can occur even when VPA levels are within the therapeutic range and hepatic function is normal.

Observation:

  • Four clinical cases of HE associated with VPA treatment are presented.
  • In these cases, the only biochemical abnormality was elevated serum ammonium levels.
  • Clinical manifestations included decreased consciousness, confusion, ataxia, and seizures, with one case showing characteristic EEG findings.

Findings:

  • Discontinuation of VPA treatment led to the remission of clinical symptoms and normalization of ammonium levels.

Related Experiment Videos

  • The study highlights that HE can be a complication of VPA therapy, irrespective of hepatic function or VPA blood concentrations.
  • Elevated ammonium levels are a key diagnostic marker for VPA-induced HE.

    • Implications:

    • Clinicians should consider monitoring ammonium levels in all patients treated with VPA, especially those exhibiting neurological symptoms.
    • Early diagnosis and withdrawal of VPA are essential for managing HE and preventing neurological sequelae.
    • This underscores the importance of understanding the complex metabolic effects of VPA to ensure patient safety.